Key Points
- CEO Zhenya Lindgardt sold 7,022 shares at an average price of $2.00, receiving $14,044 to cover tax withholding related to vested equity awards. She retained 837,848 shares after the transaction and had also sold 20,139 shares earlier in the week.
- Sera Prognostics shares opened at $2.03, near their 50- and 200-day moving averages, with a market capitalization of approximately $80.1 million. The company recently reported a quarterly loss of $0.18 per share, worse than the $0.15 consensus estimate, and revenue of $0.03 million.
- Analysts maintain a consensus “Moderate Buy” rating with an average price target of $5.50, while institutional investors own 54.64% of the company’s stock.
Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) CEO Zhenya Lindgardt sold 7,022 shares of Sera Prognostics stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $2.00, for a total value of $14,044.00. Following the sale, the chief executive officer directly owned 837,848 shares in the company, valued at $1,675,696. This trade represents a 0.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Zhenya Lindgardt also recently made the following trade(s):
- On Tuesday, September 8th, Zhenya Lindgardt sold 20,139 shares of Sera Prognostics stock. The shares were sold at an average price of $2.00, for a total transaction of $40,278.00.
Sera Prognostics Stock Down 1.0%
SERA opened at $2.03 on Friday. The firm has a 50-day simple moving average of $2.05 and a two-hundred day simple moving average of $2.02. Sera Prognostics, Inc. has a 52 week low of $1.56 and a 52 week high of $3.95. The company has a market capitalization of $80.08 million, a PE ratio of -3.03 and a beta of 0.98.
Sera Prognostics (NASDAQ:SERA - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.03). Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 47,475.72%.The company had revenue of $0.03 million during the quarter, compared to analysts' expectations of $0.07 million. As a group, sell-side analysts expect that Sera Prognostics, Inc. will post -0.62 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the stock. Weiss Ratings upgraded shares of Sera Prognostics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday. Craig Hallum assumed coverage on shares of Sera Prognostics in a report on Thursday, June 4th. They set a "buy" rating and a $6.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Sera Prognostics currently has a consensus rating of "Moderate Buy" and an average price target of $5.50.
Check Out Our Latest Analysis on Sera Prognostics
Hedge Funds Weigh In On Sera Prognostics
Several hedge funds have recently bought and sold shares of the business. Arkadios Wealth Advisors bought a new position in shares of Sera Prognostics in the first quarter worth about $25,000. Lido Advisors LLC purchased a new position in shares of Sera Prognostics in the 3rd quarter worth approximately $68,000. Cetera Investment Advisers bought a new position in shares of Sera Prognostics during the 4th quarter worth approximately $74,000. Qube Research & Technologies Ltd purchased a new stake in Sera Prognostics during the second quarter valued at approximately $92,000. Finally, Two Sigma Investments LP acquired a new stake in Sera Prognostics in the third quarter valued at approximately $97,000. Institutional investors own 54.64% of the company's stock.
Sera Prognostics Company Profile
(
Get Free Report)
Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company's flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman's risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.
Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
